Abstract
Introduction
Excessive daytime sleepiness (EDS), is estimated to affect between 10 to 20% of the population 1,2 . EDS is associated with numerous adverse clinical, behavioral and public health outcomes, including work and vehicular accidents [3] [4] [5] [6] [7] [8] [9] [10] ; reduced health-related quality of life [11] [12] [13] ; cognitive and performance deficits 14, 15 ; and increased rates of stroke and total and cardiovascular mortality 16, 17 . There are multiple mechanisms for EDS, including insufficient sleep duration due to behavioral, social or work-related factors; sleep disruption due to a sleep disorder (sleep apnea, periodic limb movement disorder); circadian misalignment; or the presence of a primary disorder of hypersomnia that affects the central sleep-wake control processes (e.g., narcolepsy).
The prevalence of EDS has increased over the past decades, likely due to an increase in working hours and availability of electronic devices 3 . A rise in EDS prevalence may also reflect the increased prevalence of obesity, which is associated with increased sleepiness 18, 19 . This association is hypothesized to be due to obesity-related co-morbidities that reduce sleep quality, including obstructive sleep apnea, as well as to metabolic and neuroendocrine effects of adipokines on wake promoting neurons 20 .
Although EDS is prevalent in the population, there appears to be large inter-individual differences in propensity for sleepiness following sleep deprivation, sleep fragmentation, or sleep apnea 21, 22 . Similarly, there is significant population variability in prevalence of EDS 23 .
Differences in sleepiness, including vulnerability or resilience to sleep disrupting influences, have been suggested to be due to genetic and other biological differences, although social and environmental influences also likely play a role 24, 25 . Generally, the bases for differences in sleepiness between populations are not well understood.
Epigenetic modifications are increasingly recognized to mediate the impact of environmental influences on gene expression and on prevalence and severity of a wide range of health outcomes, including neuropsychiatric, metabolic and cardiovascular diseases. The most studied epigenetic marker, DNA methylation (DNAm), occurs when a methyl group is added to a cytosine that is followed by a guanine on the genome (a "CpG" site). Changes in DNA methylation occur in response to a wide range of exposures, many of which are associated with sleep and sleepiness, such as obesity, diet, and stress [26] [27] [28] [29] [30] [31] [32] . Therefore, we postulated that changes in DNAm would associate with variation in sleepiness and these changes may be population-specific, providing insights into underlying susceptibility to sleepiness that may be partially attributed to environmental factors. To the best of our knowledge, there has been no reported study on DNA methylation and sleepiness.
In this paper, we performed an Epigenome Wide Association Study (EWAS) of EDS quantified by the Epworth Sleepiness Scale (ESS) in the Multi Ethnic Study of Atherosclerosis.
We leveraged the racial/ethnic diversity of the sample to explore potential differences in EWAS associations by background groups. We performed replication analysis of methylation sites-ESS associations in the Cardiovascular Health Study (CHS) and identified cis-meQTLs in genes harboring associated methylation sites for replication analysis in the UK Biobank.
Methods

Study Sample
The study population consisted of participants from the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective, longitudinal cohort study established to study factors associated with the development of cardiovascular disease. MESA clinic visits were first performed between 2000
and 2002 in six field centers across the United States when participants were free of known cardiovascular disease 33 . The subset of MESA individuals in this study is composed of those who participated in a sleep examination conducted in conjunction with MESA Exam 5 (described in detail previously 23, 33 ), and who also participated in the MESA DNAm study 34 . The blood draws for the methylation study were obtained during MESA Exam 5 (2010 -2012 35 on a random subset of MESA participants at four of the six field centers: John Hopkins University, University of Minnesota, Columbia University, and Wake Forest University. A total of 623 populations from the 1000 genomes reference data 38 . This was done to exclude loci where variation is solely due to genetic polymorphisms. We also removed any non-cg methylation probes and probes on sex chromosomes. Next, we focused on 73,082 CpG sites that had an interdecile range greater than 0.1. Methylation values in these sites are unlikely driven by technical variability and focusing on them will reduce the multiple testing burden 39 . Then, we used the software program ComBat 40 on these 73,082 CpG sites to remove any signal due to technical artifacts of chip and position on chip effects, while maintaining correlation with our primary set of covariates (self-reported ancestry, recruitment site, sex, age, and residual cell type enrichment 
Single Nucleotide Polymorphism (SNP) Data
For consenting individuals, DNA was extracted from whole blood and genotyped on Affymetrix 6.0 GWAS array. Standard quality control methods for SNP-and sample-level quality were applied, including the exclusion of participants and SNPs with over 5% missing call rates. This resulted in 895,289 genotyped variants in 615 individuals with DNAm data. For downstream analysis, we excluded SNPs with minor allele frequency (MAF) less than 1%. Further details on the genotype and quality control can be found in Vargas et al 43 . We calculated the top 5 principal components (PCs) from the Linkage-Disequilibrium pruned set SNPs with MAF≥5%. PCs were calculated in the combined sample and also in each ethnic-specific group. There were four AA individuals that had missing SNP information; therefore, the PCs were imputed with the mean value of the respective PC in the AA subset that had SNP information.
Sleep Assessments
As part of the MESA Sleep Examination (2010 -2013 , participants completed standardized questionnaires and underwent a single night in-home polysomnography (Compumedics Somte Systems, Abbotsville, Australia, AU0) and 7 day wrist actigraphy (Philips-Respironics Spectrum, Murrysville, PA), as described before 23 . The primary sleep measure was daytime sleepiness as quantified by the Epworth Sleepiness Scale (ESS), an 8-item validated instrument that asks the individual to assess likelihood of dozing off in a variety of daily activities using a 4 point (0-3) scale 44 . ESS scores vary from 0 to 24, with higher scores denoting more sleepiness 44 .
ESS was assessed within one year of blood draw for DNA methylation. We identified a set of additional sleep phenotypes/exposures that might be associated with both DNAm and ESS, and thus are potential mediators or confounders of any DNAm and ESS association. These measures were: insomnia (report of doctor diagnosed insomnia or the Women's Health Initiative (WHI)
Insomnia Rating Scale 45 , a validated scale varying from 0 to 20); Apnea-Hypopnea Index [AHI] (assessed by polysomnography as the sum of all apneas and hypopneas associated with 3% or more oxygen desaturation divided by total sleep time); overnight hypoxemia (derived by polysomnography as the percentage of sleep time the participant spent with oxyhemoglobin saturation less than 90% [Per90]); and sleep duration (actigraphy derived average sleep duration over the 7 monitoring nights as described before 23 ).
Covariates
Age, sex and race/ethnicity were self-reported. Other behavioral, socioeconomic and lifestyle exposures that may confound sleepiness-methylation associations were also assessed. Alcohol use was based on self-reported (yes/no); smoking status was classified by ever/former/never); .
Statistical Analysis
Our complete analysis approach is depicted in Figure 1 . We first describe our discovery analyses, followed by sensitivity, gene expression, local methylation expressive quantitative trait loci (cismeQTL), and replication analyses.
Discovery Analysis for Methylation-ESS Association
The primary analysis outcome was ESS score, square-root transformed to achieve approximate normality. It was analyzed in a linear regression on DNAm M-values generated following application of ComBat (as described earlier). The primary analyses were adjusted for sex, age, residual cell type enrichment, recruitment site, and the top 5 genetic PCs. We first analyzed the transformed ESS on the combined multi-ethnic sample with an additional covariate for ethnicity (EA, AA, or HA) and PCs calculated in the overall group. We then performed race/ethnic groupspecific analyses adjusting for the top five PCs calculated exclusively for each respective race/ethnicity group. To account for multiple testing, we calculated false discovery rate (FDR)
controlling q-values in each of the analyses, i.e. the multi-ethnic and each ethnic-group specific analyses 48 . An association was deemed as significant if the q-value was less than 0.1 48 , thus controlling the FDR at the 10% level in each of the analyses. We evaluated heterogeneity in any race/ethnic specific results by fitting a linear model using the overall sample with self-reported race/ethnicity interaction terms with DNAm and testing these interaction terms using an F-test via analysis of variance (ANOVA).
Sensitivity Analysis for methylation-ESS associations
We next identified behavioral, socioeconomic and lifestyle exposures, including variation in sleep and sleep disturbances, that may influence the sleepiness-methylation associations and further adjusted for these factors in sensitivity analyses conducted in significant probe-trait primary associations. Covariates considered for the sensitivity analysis were: BMI, sleep duration (actigraphy-based), insomnia, AHI, nocturnal hypoxemia [Per90], alcohol use, smoking status, CES depression scale, having less than a college education, mother having less than a college education, and dietary variables, as defined earlier in the manuscript. We also examined moderate sleep apnea defined as an AHI greater than 15, less than five hours of sleep, and overnight hypoxemia (dichotomized as Per90 greater than 5%). We only assessed variables that had a p-value less than 0.1 for their association with ESS after adjusting for age and sex. These were included together as covariates in the regression model for CpG sites with a q-value less than 0. Finally, we evaluated whether an observed change in effect size estimate between a methylation site and ESS after including each or sets of covariates was higher than by chance via permutation. We permuted the additional exposure/sensitivity variables 10,000 times and calculated the proportion of permutations in which the observed change in DNAm-ESS effect sizes was higher compared to the DNAm-ESS effect size in the un-permuted sensitivity variables.
DNAm-ESS replication analysis in the Cardiovascular Health Study (CHS)
The CHS is a population-based cohort study of risk factors for coronary heart disease and stroke in adults ≥ 65 years conducted across four field centers 49 . The original predominantly European ancestry cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists; subsequently, an additional predominantly African-American cohort of 687 persons was enrolled for a total sample of 5,888. CHS was approved by institutional review committees at each field center and individuals in the present analysis had available DNA and gave appropriate informed consent for use of genetic information. DNA methylation was measured on 336 European ancestry and 329 African-American ancestry participants at study year 5. The samples were randomly selected among participants without presence of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack at study baseline or lack of available DNA at study year 5.
Sleepiness was assessed at year 6 using the ESS.
Methylation measurements were performed at the Institute for Translational Genomics and Population Sciences at the Harbor-UCLA Medical Center--Los Angeles Biomedical
Research Institute using the Infinium HumanMethylation450 BeadChip (Illumina Inc, San Diego, CA). Quality control was performed in in the minfi R package 50-52 (version 1.12.0, http://www.bioconductor.org/packages/release/bioc/html/minfi.html). Samples with low median intensities of below 10.5 (log2) across the methylated and unmethylated channels, samples with a proportion of probes falling detection of greater than 0.5%, samples with QC probes falling greater than 3 standard deviation from the mean, sex-check mismatches, failed concordance with prior genotyping or > 0.5% of probes with a detection p-value > 0.01 were removed. In total, 11 samples were removed for sample QC resulting in a sample of 323 European-ancestry and 326
African-American samples. Methylation values were normalized using the SWAN quantile normalization method
52
. Since white blood cell proportions were not directly measured in CHS they were estimated from the methylation data using the Houseman method 53 .
We performed replication look-up of the significant (q-value<0. 
Results
Study Characteristics
The MESA sample consisted of 619 individuals (53% female) with a mean age of 68 years, with 132 AA, 202 HA, and 285 EA individuals ( 
Associations Between Sleepiness and DNAm
In the combined analysis across race/ethnic groups, no significant associations were observed between DNAm M-values and ESS. In race/ethnicity stratified analyses, significant associations were only observed in the AA group, where 61 DNAm probes were significantly associated with ESS at q-value ≤ 0.1 ( . We display the top three associations in Figure 2 . In 56 of the 61 probes, decreased methylation was associated with more sleepiness (i.e., higher ESS scores) (Supplement Table 2 ). Testing for any interaction effects between these 61 probes and selfreported ethnicity on the transformed ESS scores in the overall group identified 58 of the 61 associations with a p-value for interaction less than 0.05. 
Sensitivity Analysis
We next evaluated potential explanatory factors or confounders between the ESS-associated DNAm probes in the AA sample. Supplement Table 3 shows p-value between all considered sensitivity parameters and partial R 2 with ESS after adjusting for age and sex. WHI insomnia score, alcohol use, mother having less than a college education, and sleep duration were all associated with sleepiness (square-root transformed ESS) at a p-value of 0.1 adjusting for age and sex in the AA group (Supplementary Table 3 ). We included these four variables as additional covariates in the primary model to assess if they modified the association between DNAm and ESS. In our 61 probes, we see a change in the effect size over 10% for 45 of the probes (Supplement Table 4 ). However, the change for any individual variable was less than 10% (Supplement Table 4 ). We additionally performed a permutation study to compare the observed changes to what would be expected by chance. The change in association of 51 DNAm sites was significantly different from zero with permutation p-value<0.05, i.e., with less than 5% of permutations demonstrating the same or higher change in estimated association (Supplement Table 4 last column). Supplement Table 4 summarizes the results for the top ten probes. This suggests that the selected exposure variables confound/modify the DNAm-ESS association.
Supplemental Table 4 also shows how much the association between DNAm and transformed ESS change after the inclusion of each individual sensitivity parameter by itself. There is some evidence of confounding (effect change over 10% for 45 of the 61 probes). The majority of adjusted associations are still nominally significant (range 2.33 x 10 -3 to 4.25 x 10 -6 ) suggesting that these variables do not explain away the association between DNAm and ESS.
Replication of DNAm-sleepiness association in CHS
Of the 61 probes found significant in our discovery analysis, 60 were assayed in the CHS AA dataset (n=238). Replication analysis results are provided in Table 3 . Globally, the direction of DNAm-sleepiness associations largely agreed between MESA and CHS AA for these 61 probes (binomial p-value=0.005, Supplement Table 2 
Cis-meQTL analysis and UK Biobank replication
We performed cis-meQTL analysis for the top ten probes which mapped to seven genes that harbored significant DNAm-sleepiness associations in our AA sample. Thirty SNPs in four genes (KIFC3, KDM2B, TGFB1L1, and RAI1) passed screening step 1 (P<0.005; Supplementary 
Gene expression analysis
Comprehensive results are provided in Supplementary Tables 7 and 8 . Briefly, we considered three genes corresponding to the top 10 DNAm sites: KCTD5 (two transcripts, one DNAm site), KDM2B (one transcript and one DNAm site), and RAI1 (two transcripts and two DNAm sites).
For KDM2B, cg09411874 methylation was associated with increased expression in the HA group (p=0.04), but there was no strong evidence of KDM2B expression association with ESS (p=0.18
in the HA group). The two DNAm sites associated with RAI1 had p=0.08 in the combined cohort in association with expression of one of the RAI1 transcripts. However, the estimated association of this transcript with ESS was low (and with p>0.6 for all analyzed groups). Interestingly, larger expression of the other transcript of RAI1 was significantly associated with decreased ESS (p=0.009 in the combined cohort). We did not detect any associations in the analysis of KCTD5.
Discussion
This study reports for the first time a large-scale DNA methylation association analysis in a multi-ethnic population designed to detect DNAm markers associated with excessive daytime sleepiness. We analyzed the association both in the pooled MESA cohort and separately in each race/ethnicity group (AA, EA, and HA). In our initial discovery stage, there were 61 DNAm markers associated with sleepiness at the FDR rate of < 0.1, solely in the AA group. Of these, 60
were studied in association with the ESS score in the CHS cohort. . Here, in our study of a middle-aged to older community multi-racial sample, we found significant epigenetic findings only in the AA sample. The specificity for the findings in the AA sample could reflect differences in underlying genetic architecture that influence susceptibility to methylation or differences in environmental exposures, such as air pollution, or stress that differentially affect different groups [71] [72] [73] [74] . We explored this latter hypothesis by a series of sensitivity analyses that explored potential explanatory effects due to sleep variation and other lifestyle exposures. These analyses showed that adjusting for mother having less than a college education, alcohol use, sleep duration, and insomnia modestly attenuated the effect estimates, suggesting potential mechanisms for epigenetic findings. However, these measures do not characterize lifetime exposures nor included precise measurements of the social or physical environments, emphasizing the need for additional research that links key aspects of an individual's environmental and sociological exposures with epigenetic markers and health conditions such as sleepiness as important routes for understanding health disparities.
A few of our sleepiness associated DNAm sites are within genes that have strong evidence for associations with sleep related processes. Our most significant DNAm association with excessive sleepiness (MESA AA p-value 3.69×10 -7 ), was for cg26609398 in the KCTD5 gene. While this probe did not replicate in CHS, it was suggestive (CHS AA p-value 0.028) with the association in the same direction. KCTD5 is a mammalian ortholog of the Drosophila gene Two of our top ten associated methylation sites were within RAI1 (retinoic acid induced-1). RAI1 encodes a protein that is highly expressed in neuronal tissues and is involved in early neural differentiation and transcriptional regulation of circadian clock components 60,62-64 .
Variants in this gene have been associated with circadian rhythm disruption, several abnormal sleep traits, neurobehavioral problems and obesity 62, 64 . In addition, SNPs in RAI1 have been found to be associated with sleep apnea 59 . Moreover, our cis-meQTL analysis detected a SNP in RAI1 influencing sleepiness in an EA population from the UK Biobank. Our analysis in MESA suggests that the SNP rs9896285 has both direct and indirect (through DNAm) effect on excessive sleepiness. However, the methylation association with RAI1 did not replicate in CHS.
In another secondary analysis, we found that the expression of RAI1 in mononuclear cells was associated with ESS in MESA. More work is needed to further dissect the association of RAI1 markers with ESS.
Other findings in our study, while not as strong as KCTD5 A unique feature of this study is study of a multi-ethnic population. We identified DNAm-EDS associations that are only present in AAs. DNAm differences in these sites may explain some of the differences in EDS between AAs and EAs, highlighting potential mechanisms to explore in studies of health disparities. The main limitation of our association study is that we had small sample sizes in the group-specific analyses. Despite the limited sample size, we could directly replicate one association (after accounting for multiple testing) and observed a global consistency of the significant association between the discovery cohort MESA AA, and the replication study of CHS AAs. Such global consistency was not observed between MESA AA and CHS EA, strengthening the race/ethnic specific association evidence. Lack of further replication may relate to many factors, including the older sample of CHS participants (who are 5 years older than MESA participants, on average), biases and misclassification in selfreported sleepiness assessment 83 , and potential difference in their exposure history compared to MESA participants. Another limitation was our pruning of DNA methylation sites was stringent though similar has been done prior 39 . Given our small sample size, this was a good way to reduce the multiple testing burden by excluding probes that were likely not informative. Finally, a limitation which is shared by many epigenome-wide association studies, is the lack of identified exposure explaining the change in methylation and the group-specificity of the associations. We did study potential mechanism by considering cis-meQTLs analysis and a sensitivity analysis adjusting for various, plausible, exposure variable (sleep, lifestyle, and nutrition variables) which may be independently associated with either DNAm, ESS, or both, but these analyses did not lead to strong hypotheses about causal pathways.
In conclusion, we identified multiple DNAm probes associated with sleepiness. The majority of these probes indicated that hypomethylation was positively associated with sleepiness, with some of our top probes being near genes known to be associated with critical neuronal processes that influence sleep. Taken together, our findings suggest that these sleepiness-associated DNAm sites are related to genes that have a biologically meaningful function with regards to sleep. 
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